Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PHXM

PHAXIAM Therapeutics S.A. ADR

Dec 07 • 02:12PM ET

4.80

Dollar change -0.28
Percentage change -5.51	%

Healthcare • Biotechnology • France • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.10	Insider Own	6.35%	Shs Outstand	6.07M	Perf Week	14.56%
Market Cap	29.14M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.69M	Perf Month	7.87%
Income	-0.31M	PEG	-	EPS next Q	-	Inst Own	0.01%	Short Float / Ratio	0.24% / 1.23	Perf Quarter	-18.23%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-5.52%	Short Interest	0.01M	Perf Half Y	-47.25%
Book/sh	8.08	P/B	0.59	EPS next Y	-	ROA	-0.50%	Target Price	10.70	Perf Year	-26.15%
Cash/sh	6.82	P/C	0.70	EPS next 5Y	-	ROE	-1.22%	52W Range	3.00 - 14.00	Perf YTD	45.41%
Dividend	-	P/FCF	-	EPS past 5Y	70.34%	ROI	-0.87%	52W High	-65.71%	Beta	2.49
Dividend %	-	Quick Ratio	3.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	60.00%	ATR	0.59
Employees	49	Current Ratio	3.65	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	51.90	Volatility	15.63% 10.99%
Optionable	No	Debt/Eq	0.58	EPS Q/Q	102.69%	Profit Margin	-	Rel Volume	0.58	Prev Close	5.08
Shortable	Yes	LT Debt/Eq	0.43	Earnings	-	Payout	-	Avg Volume	11.03K	Price	4.80
Recom	1.00	SMA20	2.68%	SMA50	1.86%	SMA200	-30.95%	Volume	4,695	Change	-5.51%

Dec-06-23 04:05PM	Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023 (GlobeNewswire)
Nov-14-23 04:05PM	PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023 (GlobeNewswire)
Nov-07-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023 (GlobeNewswire) -7.01%
Oct-24-23 04:05PM	PHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureus (GlobeNewswire) -9.30%
Oct-23-23 04:05PM	TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a Buy recommendation (GlobeNewswire)
12:00PM	Loading…
12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023 (GlobeNewswire)
Jun-28-23 04:05PM	Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM (GlobeNewswire)
Jun-27-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital - June 26, 2023 (GlobeNewswire)
Jun-26-23 04:05PM	ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics (GlobeNewswire)
Jun-23-23 04:30PM	ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholders Meeting held on June 23, 2023 (GlobeNewswire)
Jun-20-23 04:05PM	ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit (GlobeNewswire) +9.99%
Jun-14-23 02:00PM	ERYTECH announces that the Commercial Court has rejected Akkadian's request to postpone the vote on the merger with Pherecydes Pharma (GlobeNewswire) +5.01%
Jun-13-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2023 (GlobeNewswire)
Jun-12-23 01:00AM	ERYTECH Responds to Akkadians Disinformation (GlobeNewswire)
Jun-05-23 02:00AM	ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes (GlobeNewswire) -7.84%
04:05PM	Loading…
May-24-23 04:05PM	ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023 (GlobeNewswire) +7.81%
May-23-23 04:05PM	ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes (GlobeNewswire)
May-16-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _May 15, 2023 (GlobeNewswire) -11.50%
May-15-23 04:45PM	ERYTECH Provides Update on the Announced Combination with PHERECYDES (GlobeNewswire) +15.84%
May-12-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _April 30, 2023 (GlobeNewswire) -20.04%
May-09-23 02:00AM	ERYTECH Provides Business and Financial Update for the First Quarter of 2023 (GlobeNewswire) +17.38%
Apr-17-23 04:05PM	ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market (GlobeNewswire) -5.67%
Apr-12-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _March 31, 2023 (GlobeNewswire)
Mar-22-23 05:05PM	ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022 (GlobeNewswire)
Mar-06-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _February 28, 2023 (GlobeNewswire) -9.58%
Feb-15-23 04:30PM	ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies (GlobeNewswire)
Feb-09-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023 (GlobeNewswire)
Jan-09-23 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022 (GlobeNewswire) +7.06%
Dec-06-22 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _October 30, 2022 (GlobeNewswire) -5.37%
Nov-21-22 04:05PM	ERYTECH Provides Business and Financial Update for the Third Quarter of 2022 (GlobeNewswire)
04:05PM	Loading…
Oct-13-22 04:05PM	ERYTECH Announces Receipt of Nasdaq Notice (GlobeNewswire)
Oct-05-22 12:00PM	Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why (Zacks)
Oct-04-22 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022 (GlobeNewswire) +9.02%
Sep-12-22 04:05PM	ERYTECH Provides Business and Financial Update for the First Half of 2022 (GlobeNewswire)
Sep-06-22 04:30PM	Monthly information related to total number of voting rights and shares composing the share capital _July 31, 2022 (GlobeNewswire)
04:30PM	Monthly information related to total number of voting rights and shares composing the share capital _August 31, 2022 (GlobeNewswire)
Aug-26-22 01:21PM	Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6% (Zacks)
Aug-25-22 06:35AM	Erytech Pharma Culls Work On Late-Stage Leukemia Asset, Evaluates Partnership Options (Benzinga) -19.12%
Aug-24-22 04:05PM	ERYTECH Provides Regulatory Update (GlobeNewswire)
Jul-07-22 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _June 30, 2022. (GlobeNewswire) +8.88%
Jun-24-22 04:05PM	Report ERYTECHs Combined Shareholders Meeting On June 24, 2022 (GlobeNewswire)
Jun-03-22 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital _May 31, 2022. (GlobeNewswire)
May-24-22 04:05PM	ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 24, 2022 (GlobeNewswire)
May-17-22 04:05PM	ERYTECH to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital April 30, 2022 (GlobeNewswire)
May-12-22 04:05PM	ERYTECH Provides Business and Financial Update for the First Quarter of 2022 (GlobeNewswire)
Apr-28-22 04:05PM	ERYTECH Announces Filing of 2021 Universal Registration Document and 2021 Annual Report on Form 20-F, as well as its 2022 financial calendar (GlobeNewswire)
Apr-25-22 02:00AM	ERYTECH Sells U.S. Manufacturing Facility and Enters Long-Term Supply Agreement with Catalent (GlobeNewswire) +37.70%
Apr-06-22 04:05PM	ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology (GlobeNewswire)
01:00PM	Monthly information related to total number of voting rights and shares composing the share capital March 31, 2022 (GlobeNewswire)
Apr-04-22 01:30AM	ERYTECH to Present Novel Vesiculation Approach at the 24th Meeting of the European Red Cell Society (GlobeNewswire) -8.33%
Mar-28-22 04:05PM	ERYTECH to Participate in the Upcoming April Investor Conferences (GlobeNewswire) -7.53%
Mar-11-22 05:18PM	ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021 (GlobeNewswire)
Mar-04-22 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital February 28, 2022 (GlobeNewswire) -7.64%
Feb-09-22 12:53PM	Erytech Shares Gain After Expanding Patent Portfolio For Treatment Of Rare Metabolic Diseases (Benzinga)
Feb-08-22 04:05PM	ERYTECH Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases (GlobeNewswire)
12:00PM	Monthly information related to total number of voting rights and shares composing the share capital January 31, 2022 (GlobeNewswire)
Jan-10-22 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital December 31, 2021 (GlobeNewswire)
Jan-03-22 04:05PM	ERYTECH to Participate in the Upcoming January Virtual Investor Conferences (GlobeNewswire)
Dec-14-21 01:30AM	ERYTECH Announces $7.85 Million Registered Direct Offering (GlobeNewswire)
Dec-13-21 04:05PM	ERYTECH Announces Presentation of Results of Expanded Access Program in ALL at 2021 ASH Annual Meeting and Acceptance of Two Abstracts at ASCO GI (GlobeNewswire)
Dec-10-21 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital November 30, 2021 (GlobeNewswire)
Dec-01-21 09:22AM	Company News for Dec 1, 2021 (Zacks) -8.09%
Nov-29-21 04:05PM	ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors (GlobeNewswire)
Nov-15-21 04:05PM	ERYTECH Provides Business and Financial Update for the Third Quarter of 2021 (GlobeNewswire)
01:30AM	ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-10-21 01:30AM	ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal (GlobeNewswire)
Nov-09-21 02:00AM	ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference (GlobeNewswire)
Nov-05-21 01:21PM	Monthly information related to total number of voting rights and shares composing the share capital October 30, 2021 (GlobeNewswire) -7.17%
Oct-25-21 12:11PM	Mid-Day Market Update: Crude Oil Rises Over 1%; ERYTECH Pharma Shares Plummet (Benzinga) -39.96%
10:17AM	Mid-Morning Market Update: Markets Edge Higher; Kimberly Clark Cuts FY21 Forecast (Benzinga)
09:31AM	ERYTECH Pharma Stock Tumbles after Pancreatic Cancer Trial Disappoints (Investing.com)
01:00AM	ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer (GlobeNewswire)
Oct-07-21 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital September 30, 2021. (GlobeNewswire) +5.08%
Oct-04-21 04:05PM	ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer (GlobeNewswire)
Sep-28-21 04:05PM	ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech (GlobeNewswire)
Sep-22-21 12:30PM	ERYTECH Announces the Availability of its Half-Year Financial Report 2021 (GlobeNewswire)
Sep-20-21 04:05PM	ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021 (GlobeNewswire) +7.94%
Sep-15-21 04:05PM	ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update (GlobeNewswire)
Sep-06-21 04:05PM	ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-03-21 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital August 31, 2021 (GlobeNewswire)
Aug-30-21 04:05PM	ERYTECH to Participate in the Citi 16th Annual BioPharma Conference (GlobeNewswire) +7.50%
Aug-24-21 04:30PM	ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer (GlobeNewswire)
Aug-05-21 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital July 30, 2021 (GlobeNewswire)
Jul-30-21 08:50AM	Erytech Pharma stock nearly doubles on heavy volume after ALL treatment granted Fast Track designation (MarketWatch) +54.99%
Jul-29-21 04:05PM	ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL (GlobeNewswire)
Jul-27-21 01:30AM	ERYTECH to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-21-21 04:05PM	ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients (GlobeNewswire)
Jul-06-21 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital June 30, 2021 (GlobeNewswire)
Jun-25-21 04:30PM	Report - Erytechs Combined Shareholders Meeting on June 25, 2021 (GlobeNewswire)
Jun-07-21 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital May 31, 2021 (GlobeNewswire)
May-26-21 04:30PM	ERYTECH to Participate in Upcoming Virtual Investor Conferences in June (GlobeNewswire)
May-25-21 04:00PM	Erytechs Combined Shareholders Meeting on June 25, 2021 (GlobeNewswire) -7.44%
May-07-21 12:00PM	Monthly information related to total number of voting rights and shares composing the share capital April 30, 2021 (GlobeNewswire)
May-04-21 04:30PM	ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021 (GlobeNewswire)
Apr-29-21 02:30AM	ERYTECH Announces $30.0 Million Registered Direct Offering (GlobeNewswire)
Apr-28-21 07:30PM	ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call (GlobeNewswire)
Apr-20-21 01:30AM	ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL (GlobeNewswire)
Apr-19-21 01:30AM	ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer (GlobeNewswire)
Apr-07-21 04:30PM	ERYTECH to Participate in Upcoming Virtual Investor Conferences in April (GlobeNewswire)

Phaxiam Therapeutics SA is a biopharmaceutical company, which develops red blood cell-based therapeutics for severe forms of cancer and orphan diseases. It operates through the following technical platforms: ERYCAPS, ERYCEV and ERYTECH. The ERYCAPS which uses a novel technology to encapsulate drug substances inside red blood cells. The ERYCEV focuses on potential of drug-loaded extracellular vesicles, derived from red blood cells. ERYTECH developing product candidates for patients with unmet medical needs. The company was founded in 2004 and is headquartered in Lyon, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PHXM

PHAXIAM Therapeutics S.A. ADR

Upgrade your FINVIZ experience